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RCM as [(number of normal ‘activities’ days missed due
to migraine)  (number of normal ‘activities’ days per-
formed with migraine symptoms)(100%  % effective-
ness while working with symptoms)/100%]  (daily
wages). Daily wages for the corresponding occupational
category were used for patients with paid jobs. For pa-
tients without paid jobs, a daily wage of $0 and a daily
wage for private ‘household workers’ ($8) was assigned
for the HCA and RCM, respectively. RESULTS: There
were 178 patients who completed the study (90% female,
96% Caucasian, average age 39 years). There were 82%
of patients with paid jobs and 18% without paid jobs.
The 6 month NWPC lost were $184,143 and $203,505
using the HCA and RCM, respectively. CONCLUSION:
The RCM yields a higher estimate of NWPC of mi-
graineurs than the HCA. The HCA may underestimate
the NWPC of migraineurs. The method used to value
NWPC impacts the results of studies that are conducted
from the societal perspective.
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INTRODUCTION: The increase of patient-based assess-
ments in clinical trials has emphasized the need for cross-
culturally valid instruments to pool data across countries.
The Work Limitations Questionnaire (WLQ) consists of
25 questions divided into 4 scales, was developed in US
English and is designed for the assessment of the impact
of health problems on work. METHODS: Prior to use in
an international trial, the original questionnaire under-
went linguistic validation in 3 languages. Coordinated by
a QoL specialist in each target country, an internationally
recognised translation methodology was followed: pre-
liminary versions in Canadian French and US Spanish
were established after forward/backward translation.
The Canadian English version was established after a re-
view of the original by a QoL specialist in Canada.
Throughout the process the author clarified the concepts
underlying each item. RESULTS: Linguistic and concep-
tual issues arose during the translation process. The no-
tion of “work without stopping to take breaks or rests”
could not be translated literally, as in some countries, it is
illegal not to take breaks. It was therefore translated as
“work without stopping to take more breaks than
usual”. Likewise, the alternative use of “clients” and
“customers” in the original could be translated by only
one word in the translations. CONCLUSION: The steps
performed ensure the conceptual equivalence between the
original and the preliminary language versions. Testing
on a sample target population in each country and the
comparison of all languages will ensure the clarity, ap-
propriateness of wording and acceptability of the transla-
tions as well as their international harmonization. Psy-
chometric testing will be important to ensure similar
relationships among scales across countries.
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Simulation modeling can be used to obtain cost-effective-
ness information on drugs still in early development. OB-
JECTIVE: To construct a disease-based simulation model
characterizing the current patterns of treatment of os-
teoporosis and their associated clinical and economic
outcomes. The model can then be used to estimate the
marginal value of each proposed clinical characteristic of
a new drug for osteoporosis. METHODS: We performed
a systematic literature review of the epidemiology, treat-
ment guidelines and patterns of osteoporosis, as well as
of previous economic models and cost-effectiveness liter-
ature in this area. Interviews with clinicians and epidemi-
ologists were conducted to identify important parameters
for inclusion in the model. Information from these
sources was utilized to develop the model. RESULTS: A
state transition model has been constructed. Twenty-five
health states are used, with the inclusion of four fracture
sites (hip, wrist, vertebral and other), and other diseases
(i.e., breast cancer, coronary heart disease) that osteoporo-
sis interventions may impact. Simulation duration, co-
hort size, patient age matrices and distribution of initial
health states can all be varied, allowing a number of as-
sumptions to be tested. Quality adjusted life year values
and costs for the given year and subsequent years associ-
ated with each health state are included. The impact of
relative risks associated with each intervention are incor-
porated into the model, together with start and rise
times, fall and stop times. CONCLUSION: Through sim-
ulation modeling, data can be combined to estimate clini-
cal outcomes and economic consequences of osteoporosis
treatment early in the drug development process. Such in-
formation can then be used to establish the key clinical
characteristics that will need to be obtained in order to
achieve reimbursement.
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OBJECTIVE: The purpose of this investigation was to
compare the experiences of two US corporations, each
employing over 50,000 workers and each offering a com-
prehensive benefit package, in terms of direct (i.e., medi-
cal and pharmaceutical) and indirect (i.e., sick leave and
disability) costs of illness. METHODS: Based on a 1996
sample of workers (n  9439), retrospective medical and
pharmaceutical claims at the employee level were linked
with contemporaneous archival measures of productiv-
ity, including sick leave and disability. These results were
normalized to the age-gender distribution of the US labor
force. To assess the comparability of experiences at each
company, direct and indirect burdens of illness were ex-
amined both in the aggregate as well as at the disease-
group level. RESULTS: The average annual cost of illness
per employee was $3,272 in Company A (59% medical,
9% pharmaceutical, and 32% work loss) and $3,574 in
Company B (44% medical, 9% pharmaceutical, and
47% work loss). Although musculoskeletal diseases rep-
resented the greatest total cost outlay for both companies
(i.e., 10% at Company A, 16% at Company B), the dis-
tribution of direct and indirect costs varied by diagnostic
grouping. CONCLUSIONS: A traditional focus on direct
costs alone would vastly understate the impact of illness
to the employer, since for every dollar of direct expendi-
tures, these companies spent between $0.47 and $0.87 on
additional indirect costs. Worksite and employee health
management programs tailored to the characteristics of
the particular workforce in question could help maximize
return on investment in employee health.
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Health Outcomes Research (OR) groups exist in most
major pharmaceutical companies and are currently chal-
lenged to quantify their productivity and value to the or-
ganization. Per a recent Tufts survey, industry leaders ex-
pect continued growth in OR departments substantiating
the need for metrics. METHODS: Our OR Department,
positioned within Clinical Research, was approached by
upper management to create a metrics reporting system.
The group discussed a comprehensive list of departmen-
tal activities until core items were agreed upon. Using a
0-10 scale, items were ranked by perceived value to the
company using the Delphi technique. To approximate
time expenditure, complexity categories (1  simple, 2 
moderate, 3  complex), based on estimates of average
number of workdays to complete each activity, were as-
signed to each item. RESULTS: An initial list of 20 items
was reduced by the group to yield 11 core items: publica-
tions (1.8  Delphi weight), models (1.4), strategic plans
(1.3), protocols (0.9), instrument development (0.9), re-
search reports (0.9), abstracts (0.7), reviews (0.6), analy-
sis plans (0.6), presentations (0.5), IPMs (0.4). The value-
score was generated by multiplying the count of each
item by its Delphi-weight then summed to result in a
composite value-score. The complexity-score was calcu-
lated similarly. These two scores, reported separately to
enhance understanding of both output and labor, were
divided by the number of team members to produce pro-
ductivity units per headcount. CONCLUSION: This met-
rics system represents one approach to valuing OR group
contributions. We have implemented a validation and
QA process to observe performance over time and assess
appropriateness of the items selected. This system does
not capture activities conducted to support departmental
and organizational infrastructure. Therefore, is not ap-
propriate for calculating standard costs or for valuing all
contributions attributable to OR groups. In addition to
concisely communicating OR activities to upper-manage-
ment, metrics help team members focus on value-added
activities and project prioritization.
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OBJECTIVES: Consumer preferences and willingness-to-
pay (WTP) were measured for a new dental anesthetic
(dental gel) versus existing anesthetic options for peri-
odontal recall cleanings. METHODS: The study was
conducted by developing and administering a computer-
based interactive survey to study subjects. First, clinical
information was provided, describing periodontal dis-
ease, recall cleaning visits, and anesthetic options (no
freezing, dental needle, and dental gel). Subjects were
asked to choose which freezing option they would prefer,
if they required freezing. Strength of preference for dental
gel was measured using WTP: (1) at the subject’s point of
consumption, and (2) as a monthly dental insurance pre-
mium, for any dental plan beneficiary at the point of con-
sumption. RESULTS: Both recall patients (n  97) and
general population subjects (n  196) participated in the
study. The majority of general subjects (81.0%) and re-
call subjects (82.5%) chose dental gel over other options.
The majority of general subjects (86.7%) and recall sub-
jects (83.8%) who preferred dental gel were willing to
pay for dental gel. The median WTP to have dental gel
available at the point of consumption was $20.00 per
visit for the general population, and $10.00 for the recall
population. The majority of general subjects (72.4%)
and recall subjects (73.2%) were willing to pay an insur-
ance premium for dental gel, even if they did not person-
ally prefer dental gel. The median monthly premium was
$2.00 per month for both groups. CONCLUSIONS:
Dental gel was overwhelmingly preferred by general and
